The elevated expression of YY1 is significantly correlated with progression of advanced prostate cancer. (A, B) Boxplots showing overall YY1 mRNA levels among the prostate cancer patient cohorts reported by Singh et al. (29) (A) and Tomlins et al (30) (B), relative to their respective normal control tissues. (C, D) Representative images (C; 10×) and quantification (D) of YY1 immunohistochemistry (IHC) staining of thirteen paired prostate tumor and adjacent normal/benign tissues. (E) Immunoblotting for YY1 using total protein lysates of the paired normal/benign (B) and tumor (T) tissues from prostate cancer patients. β-actin acts as a loading control. (F, G) Representative images (F) and quantification (G) of YY1 IHC staining by using tissue microarrays (TMA) that contained the samples of benign prostates (n = 136), primary prostate adenocarcinoma (AdenoCa; n = 138) and CRPC (n = 55).